bioRxivCancer BiologyPreprint
High Drug-Loading Rucaparib-FdUMP Nanocarriers for Colorectal Cancer Combination Therapy
Anna Erika WeberiD, Christian Ritschel, Claus FeldmanniD, Susanne KossatziD
- Citations
- 0
Abstract
Combination chemotherapy remains the standard of care for advanced colorectal cancer, yet the clinical benefit is limited by off-target toxicity and insufficient tumor drug exposure. Co-administration of 5-fluorouracil (5-FU) with poly(ADP-ribose) polymerase (PARP) inhibitors such as rucaparib (RUC) can potentiate 5-FU-induced DNA damage by suppressing DNA repair but achieving robust co-delivery at defined ratios and high payload remains challenging. Here, we report high drug-loading core@shell nanocarriers (RUC@[ZrO][FdUMP]) that co-deliver RUC and the active 5-FU metabolite fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP). Nanocarriers were synthesized via a solvent-antisolvent approach to form a tocopherol phosphate (TocP)-stabilized RUC core followed by the growth of an amorphous [ZrO][FdUMP] shell, yielding an overall drug load of 59 wt%. Dual fluorescence (shell incorporation of DUT647 and intrinsic RUC emission) enabled quantitative tracking and revealed rapid uptake in HCT116 and HT29 colorectal cancer cells and tumor accumulation in a subcutaneous HT29 xenograft. In vitro, RUC@[ZrO][FdUMP] showed cytotoxicity comparable to the free-drug combination, induced S-phase arrest, and increased {gamma}H2AX foci, consistent with replication stress and DNA double-strand break formation. Drug-drug interaction analysis demonstrated synergistic activity of the RUC/FdUMP pair in colorectal cancer cells. Together, these results establish RUC@[ZrO][FdUMP] as a high-payload nanocarrier platform for co-delivering synergistic PARP inhibitor/fluoropyrimidine combinations, supporting further development and in vivo evaluation of this co-delivery strategy for colorectal cancer therapy. TOC Graphics O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=50 SRC="FIGDIR/small/727099v1_ufig1.gif" ALT="Figure 1"> View larger version (15K): org.highwire.dtl.DTLVardef@dd9ad6org.highwire.dtl.DTLVardef@e07aecorg.highwire.dtl.DTLVardef@1a63505org.highwire.dtl.DTLVardef@e30d58_HPS_FORMAT_FIGEXP M_FIG C_FIG
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cellular uptake of folate-olaparib conjugates via folate receptor-mediated endocytosis: Potential for selective delivery of DNA damage response inhibitors into tumour cells
Vassilios Bavetsias, Lisa Pickard, … Udai Banerji·bioRxiv·Sep 24, 2026
- Folate receptor targeted nanoparticles containing niraparib and doxorubicin for treatment of high grade serous ovarian cancer
L. Wang, J. C. Evans, … C. Allen·bioRxiv·Aug 29, 2022
- Transferrin Receptor 1-targeted polymersomes therapy for Colorectal Cancer
Ariana Pina, Elisa Mastrantuono, … Diana Matias·Materials Today BioPeer-reviewed·Sep 3, 2025
- Novel polymeric fluoropyrimidine CF10 demonstrates superior therapeutic index and survival advantage in patient-derived models of 5-fluorouracil-refractory colorectal cancer
Naresh Sah, Tasmin Rahman Omy, … Komaraiah Palle·bioRxiv·Apr 8, 2026
- Photodynamic therapy in colorectal cancer using photosensitizers functionalized by arene-ruthenium complexes
J. Massoud, A. Pinon, … B. Liagre·bioRxiv·Oct 11, 2022
- Loss-of-Function genetic Screen Unveils Synergistic Efficacy of PARG Inhibition with Combined 5-Fluorouracil and Irinotecan Treatment in Colorectal Cancer
Cristina Queralt, Cristina Moreta-Moraleda, … Eva Martinez‐Balibrea·Clinical and Translational MedicinePeer-reviewed·Dec 1, 2025